Stock Screener App

Frei -

Installieren

11.45

1.38% -0.16

Vorhandelsmarkt: 11.45

Oculis Holding Ag (OCS)

Überblick Nachrichten Preisverlauf Forum Prognose

Oculis Holding Ag Aktie (OCS) Neueste Nachrichten

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com

Oculis executive Sylvia Cheung reports June 10 share purchase - Stock Titan

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment - Streetwise Reports

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - AOL.com

OCS News | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill

Oculis shelves FDA filing after phase 3 DME trials miss key vision goals - MSN

Oculis enrolls first patient in licaminlimab PREDICT-1 DED trial - Optometry Times

Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026 - Pluang

Oculis to present Privosegtor's progress for optic neuritis treatment at Clinical Trials Summit 2026 - Pluang

Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm - PR Newswire

H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com UK

H.C. Wainwright reiterates Oculis stock rating on trial start By Investing.com - Investing.com Australia

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - The Manila Times

Oculis Holding AG to Present on Privosegtor at Clinical Trials at the Summit 2026 - Quiver Quantitative

Experimental eye drug Privosegtor aims to protect vision in optic neuritis - Stock Titan

Bronstein, Gewirtz & Grossman, LLC Encourages Oculis Holding AG (OCS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Oculis executive and board member buys more company shares - Stock Titan

Oculis randomizes first patient in precision dry eye disease trial - grafa.com

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - The Manila Times

New dry eye trial tailors licaminlimab to genes; only 13% see sustained relief - Stock Titan

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Oculis to present updates on late-stage eye disease treatments at Goldman Sachs Healthcare Conference - Pluang

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - The Manila Times

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud I - GuruFocus

Oculis Holding AG to Provide Update on Late-Stage Portfolio at 47th Annual Goldman Sachs Global Healthcare Conference - Quiver Quantitative

Price-Driven Insight from (OCS) for Rule-Based Strategy - Stock Traders Daily

2026-06-08 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Investors to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse

Oculis Holding AG (OCS) Securities Fraud InvestigationLevi & Korsinsky - Morningstar

Nan Fung Group Cuts Oculis Stake Amid Phase 3 Trial Failure and Stock DeclineNews and Statistics - IndexBox

Lost Money on Oculis Holding AG (OCS)? Contact Levi & Korsinsky About Investigation - TMX Newsfile

Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Gross - The National Law Review

2026-06-07 | Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Oculis Holding AG (OCS) And Encourages Stockholders to Reach Out - ACCESS Newswire

2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Oculis Holding AG (OCS) And Encourages Stockholders to Reach Out | NDAQ:OCS | Press Release - Stockhouse

Oculis Holding (OCS) Is Down 60.1% After OCS-01 Trial Failure And Pipeline Pivot – Has The Bull Case Changed? - simplywall.st

Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Stockholders to Connect - ACCESS Newswire

OCS Stock Price and Chart — NASDAQ:OCS - TradingView

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AGOCS - PR Newswire

Levi & Korsinsky Announces Investigation of Securities Claims Against Oculis Holding AG (OCS) - GlobeNewswire

OCS Maintained by JP Morgan -- Price Target Lowered to $23.00 - GuruFocus

Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

2026-06-03 | Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse

OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud - Business Wire

OCS Maintains by Baird -- Price Target Lowered to $38.00 - GuruFocus

ROIV

$30.41

1.27%

MRNA

$55.40

6.27%

BNTX

$89.50

1.43%

RPRX

$54.21

0.11%

ONC

$263.92

1.60%

RVMD

$156.58

2.17%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters